Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Benign Hematology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Benign Hematology

Expert Opinion / My Approach · April 10, 2019

MY APPROACH: Dual Antiplatelet or Antithrombotic Therapy After MI: A Hematologist’s Perspective

Written by
Michael H. Kroll MD

 

 Save  Recommend
 Share

Additional Info

  1. US Preventative Services Task Force. Aspirin use to prevent cardiovascular disease and colorectal cancer: preventive medication. Published April 2016.
  2. American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. J Am Coll Cardiol. 2016;68(10):1082-1115.
  3. Turgeon RD, Ackman ML, Babadagli HE, et al. The role of direct oral anticoagulants in patients with coronary artery disease. J Cardiovasc Pharmacol Ther. 2018 Aug 20:1074248418795889. doi: 10.1177/1074248418795889. [Epub ahead of print.]
  4. Bonow RO, Braunwald E. The evidence supporting cardiovascular guidelines: is there evidence of progress in the last decade? JAMA. 2019;321(11):1053-1054.
  5. Connolly SJ, Eikelboom JW, Bosch J, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomized, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):205-218.
  6. Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior MI. N Engl J Med. 2015;372(19):1791-1800.
  7. Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomized, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219-229.
  8. Ohman EM, Roe MT, Steg PG, et al. Clinically significant bleeding with low dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ASC-1): a double blind multicenter, randomized trial. Lancet. 2017;389(10081):1799-1808.
  9. Braunwald E. An important step for thrombocardiology. N Engl J Med. 2017;377(14):1387-1388.

Disclosure statements are available on the authors' profiles:

Michael Kroll MD

Further Reading

Recently Updated